Karyopharm Therapeutics(US:KPTI)2025-02-19 13:24Financial Performance & Guidance - Total revenue for 2024 was $1452 million, with XPOVIO net product revenue contributing $1128 million[91, 90] - Q4 2024 XPOVIO net sales reached $293 million[93] - The company projects total revenue of $140-$155 million for 2025, with U S XPOVIO net product revenue expected to be $115-$130 million[114] - R&D and SG&A expenses for 2025 are estimated at $240-$255 million, including ~$20 million in non-cash stock compensation[114] Myelofibrosis Program - The peak U S revenue opportunity for selinexor in myelofibrosis is estimated at ~$1 billion[7, 16, 98, 120] - Top-line data from the Phase 3 SENTRY trial of selinexor in myelofibrosis is expected in 2H'25[7, 117, 120] - In a Phase 1 trial, 79% of ITT patients achieved SVR35 at week 24 with selinexor 60 mg + ruxolitinib[32, 53] - In the Phase 1 trial, an average 185 point improvement in Abs-TSS was observed in the efficacy evaluable population at week 24 with Selinexor + ruxolitinib[12, 41, 53] Endometrial Cancer Program - The Phase 3 XPORT-EC-042 trial is focused on TP53 wild-type endometrial cancer patients, with top-line data anticipated in mid-2026[58, 60, 61, 69, 79, 82] - In a SIENDO trial subgroup analysis, the median PFS benefit in TP53 wild-type/pMMR patients was 395 months[73, 74]